Alexandre de Nonneville (Alexandre De Nonneville)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 25

Top Venues

Cancers

Cancer medicine

Pharmaceutics

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer medicine 13 (3) (2024)
Alexandre de Nonneville, Elsa Kalbacher, Francesco Cannone, Arnaud Guille, José Adelaïde, Pascal Finetti, Maria Cappiello, Eric Lambaudie, Giuseppe Ettore, Emmanuelle Charafe, Emilie Mamessier, Magali Provansal, François Bertucci, Renaud Sabatier
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization. Molecular oncology (2024)
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer medicine 13 (3) (2024)
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer medicine 13 (3) (2024)
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer medicine (2024)
Alexandre Giraudo, Renaud Sabatier, Frederique Rousseau, Alexandre de Nonneville, Anthony Goncalves, Maud Cecile, Cecile Braticevic, Frederic Viret, Lorene Seguin, Maria Kfoury, Dorothée Naudet, Marie Hamon, Louis Tassy
The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? Cancers 16 (10) (2024)
Alexandre Giraudo, Renaud Sabatier, Frederique Rousseau, Alexandre de Nonneville, Anthony Goncalves, Maud Cecile, Cecile Braticevic, Frederic Viret, Lorene Seguin, Maria Kfoury, Dorothée Naudet, Marie Hamon, Louis Tassy
The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? Cancers 16 (10) (2024)
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival. Cancer medicine 13 (3) (2024)
Alexandre de Nonneville, Pascal Finetti, Laurys Boudin, Emilie Denicolaï, Daniel Birnbaum, Emilie Mamessier, François Bertucci
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. Pharmaceutics 15 (3) (2023)
Ondine Dufour, François Bertucci, Laurys Boudin, Renaud Sabatier, Anthony Goncalves, Alexandre de Nonneville
Efficacy of Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Acute Intracranial Hypertension Because of Brain Metastases. JCO precision oncology 7 (2023)
Alexandre de Nonneville, Pascal Finetti, Laurys Boudin, Emilie Denicolaï, Daniel Birnbaum, Emilie Mamessier, François Bertucci
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. Pharmaceutics 15 (3) (2023)
Alexandre de Nonneville, Pascal Finetti, Laurys Boudin, Emilie Denicolaï, Daniel Birnbaum, Emilie Mamessier, François Bertucci
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. Pharmaceutics 15 (3) (2023)
Gilles Houvenaeghel, Monique Cohen, Marc Martino, Fabien Reyal, Jean-Marc Classe, Marie-Pierre Chauvet, Pierre-Emmanuel Colombo, Mellie Heinemann, Eva Jouve, Pierre Gimbergues, Anne-Sophie Azuar, Charles Coutant, Anthony Goncalves, Alexandre de Nonneville
Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery. Cancers 15 (18) (2023)
Gilles Houvenaeghel, Alexandre de Nonneville, Guillaume Blache, Max Buttarelli, Camille Jauffret, Djamel Mokart, Laura Sabiani
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes. Journal of gynecologic oncology 33 (3) (2022)
Gilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, Jean-Marc Classe, Chafika Mazouni, Marie-Pierre Chauvet, Fabien Reyal, Christine Tunon de Lara, Eva Jouve, Roman Rouzier, Emile Daraï, Pierre Gimbergues, Charles Coutant, Anne Sophie Azuar, Richard Villet, Patrice Crochet, Sandrine Rua, Marie Bannier, Monique Cohen, Jean-Marie Boher
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases. Cancer medicine (2022)
Alexandre de Nonneville, Sebastien Salas, François Bertucci, Alexander P Sobinoff, José Adélaïde, Arnaud Guille, Pascal Finetti, Jane R Noble, Dimitri Churikov, Max Chaffanet, Elise Lavit, Hilda A Pickett, Corinne Bouvier, Daniel Birnbaum, Roger R Reddel, Vincent Geli
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. EMBO molecular medicine 14 (10) (2022)
Alexandre de Nonneville, Pascal Finetti, Emilie Mamessier, François Bertucci
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute 114 (7) (2022)
Alban Macagno, Alexandre de Nonneville, Pierre Annede, Gilles Piana, Isabelle Pougnet, Nassima Daidj, Laurence Moureau-Zabotto, Julien Darreon, Laetitia Padovani, François Bertucci, Naji Salem
Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease. Current oncology (Toronto, Ont.) 29 (3) (2022)
Alexandre de Nonneville, Pascal Finetti, Maelle Picard, Audrey Monneur, Maria Abbondanza Pantaleo, Annalisa Astolfi, Jerzy Ostrowski, Daniel Birnbaum, Emilie Mamessier, François Bertucci
CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response. Cancers 14 (5) (2022)
Laurys Boudin, Alexandre de Nonneville, Pascal Finetti, Geoffrey C Guittard, Jacques A Nunès, Daniel Birnbaum, Emilie Mamessier, François Bertucci
CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. Cancers 14 (14) (2022)
Gayathri R Devi, Pascal Finetti, Michael A Morse, Seayoung Lee, Alexandre de Nonneville, Steven Van Laere, Jesse Troy, Joseph Geradts, Shannon J McCall, Francois Bertucci
Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers 13 (11) (2021)
Alexandre de Nonneville, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier, François Bertucci
WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (17) (2021)
Alexandre de Nonneville, Roger R Reddel
Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX. Nature communications 12 (1) (2021)
Alexandre de Nonneville, Camille Jauffret, Anthony Gonçalves, Jean-Marc Classe, Monique Cohen, Fabien Reyal, Chafika Mazouni, Marie-Pierre Chauvet, Nicolas Chopin, Pierre-Emmanuel Colombo, Eva Jouve, Emile Darai, Roman Rouzier, Charles Coutant, Pierre Gimbergues, Anne-Sophie Azuar, Christine Tunon de Lara, Eric Lambaudie, Gilles Houvenaeghel
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast cancer research and treatment 175 (2) (2019)
Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean M Classe, Monique Cohen, Eric Lambaudie, Fabien Reyal, Christophe Scherer, Xavier Muracciole, Pierre E Colombo, Sylvia Giard, Roman Rouzier, Richard Villet, Nicolas Chopin, Emile Darai, Jean R Garbay, Pierre Gimbergues, Laura Sabiani, Charles Coutant, Renaud Sabatier, François Bertucci, Jean M Boher, Gilles Houvenaeghel
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast cancer research and treatment 162 (2) (2017)

Alexandre de Nonneville.css-eqlu8i{font-size:small;padding-left:4px;} (Alexandre De Nonneville)

Publication Activity (10 Years)

Top Topics

Top Venues

Alexandre de Nonneville (Alexandre De Nonneville)